Consortium for Design of TB Drug Regimens (UM1 Clinical Trial Not Allowed)

The summary for the Consortium for Design of TB Drug Regimens (UM1 Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Consortium for Design of TB Drug Regimens (UM1 Clinical Trial Not Allowed): The purpose of this FOA is to establish a consortium of tuberculosis (TB) preclinical and clinical experts to systematically refine preclinical models by analyses of relevant pre-clinical and clinical data, and to provide results from optimized models to identify the most promising combination regimens for clinical testing

Federal Grant Title:	Consortium for Design of TB Drug Regimens (UM1 Clinical Trial Not Allowed)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-AI-22-059
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.855
CFDA Descriptions:	Information not provided
Current Application Deadline:	February 7th, 2023
Original Application Deadline:	February 7th, 2023
Posted Date:	September 21st, 2022
Creation Date:	September 21st, 2022
Archive Date:	March 15th, 2023
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	September 21st, 2022

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement: https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-059.html
Grant Announcement Contact: NIH Grants Information
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Similar Government Grants: • Development of Alternative Human Models of Radiation-Induced Injuries (Extracorporeal Syst...; • Discovery and Development of Novel Therapeutics for Select Fungal Pathogens (R21/R33 Clini...; • Strategies for Eliminating HIV Proteins (R21 Clinical Trial Not Allowed); • Strategies for Eliminating HIV Proteins (R01 Clinical Trial Not Allowed); • Promoting Innovative Research in Treponema pallidum Pathogenesis (R21 Clinical Trial Not A...; • Center for HIV/AIDS Vaccine Immunology (CHAVI); • Genomics of Transplantation Cooperative Research Program; • Asthma and Allergic Diseases Cooperative Research Centers
More Grants from the National Institutes of Health: • Human Brain Single-cell Genomics Explorer (U24 - Clinical Trial Not Allowed); • Interventions to expand cancer screening and preventive services to ADVANCE health in popu...; • Continuation or Revision of NIDCR Clinical Trial Planning and Implementation Cooperative A...; • Single Source: NCI National Clinical Trials Network - Canadian Collaborating Clinical Tria...; • NCI National Clinical Trials Network - Network Lead Academic Participating Sites (UG1 Clin...